Andrew Cheng - 09 Dec 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President & CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 09 Dec 2022
Transactions value $: $0
Form type: 4
Filing time: 13 Dec 2022, 19:30:59 UTC
Previous filing: 02 Dec 2022
Next filing: 20 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Award	$0	+52.4K	+16.88%	$0.00	362K	09 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Award	$0	+236K		$0.00	236K	09 Dec 2022	Common Stock	236K	$42.95	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2	This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.